Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02862067 · ClinicalTrials.gov registry record
SGLT2 Inhibition in Diabetes and Heart Failure
A clinical trial of Diabetes Mellitus, Type 2 and Heart Failure, Systolic, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- 18
- Enrollment target
- 1
- Study location
NCT02862067: Completed study of Diabetes Mellitus, Type 2 and Heart Failure, Systolic, sponsored by Virginia Commonwealth University.
NCT02862067 is a study of Diabetes Mellitus, Type 2 and Heart Failure, Systolic that has completed, run by Virginia Commonwealth University. The registered enrollment target is 18 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02862067, a study of Diabetes Mellitus, Type 2 and Heart Failure, Systolic, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the effects of SGLT2 inhibition with empagliflozin on cardio-respiratory fitness in patients with systolic heart failure.
Primary Outcome
To measure the effects of Empagliflozin on cardiorespiratory fitness in patients with type 2 diabetes and heart failure with reduced ejection fraction or systolic heart failure. The effects on CRF are determined by measuring changes in peak VO2 (mL/kg/min) and the VE/VCO2 slope.
Conditions Studied
Interventions
- OTHER Assessment of cardiorespiratory fitness
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-07 |
| Est. Completion | 2018-01-16 |
What the finished NCT02862067 record still lists
NCT02862067 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Assessment of cardiorespiratory fitness is the first listed.
NCT02862067 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT02862067 about?
NCT02862067 is a clinical study titled "SGLT2 Inhibition in Diabetes and Heart Failure". To determine the effects of SGLT2 inhibition with empagliflozin on cardio-respiratory fitness in patients with systolic heart failure.
What is the current status of trial NCT02862067?
This trial is currently completed. The enrollment target is 18 participants. The study started on 2016-07. Estimated completion is 2018-01-16.
What conditions does trial NCT02862067 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Heart Failure, Systolic.
What interventions are being tested in trial NCT02862067?
The interventions under investigation include: Assessment of cardiorespiratory fitness (OTHER).
Who is sponsoring clinical trial NCT02862067?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02862067 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02862067's enrollment target sits among peer trials
18 330th of 348 higher than 19 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Drug Interaction Potential of Pro-Inflammatory Conditions
RECRUITING
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
RECRUITING · Phase 1
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia